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Abstract 
The prevention and treatment of infectious diseases is highly dependent on the availability of reliable diagnostic tests 
and protective or therapeutic vaccines. There also exists an urgent need to develop reliable biomarkers to monitor 
treatment success and to predict disease progression from asymptomatic to symptomatic disease in several disease 
scenarios. The elucidation of the disease-relevant antigens that elicit the protective immune responses is critical and 
required for the development of biomarkers, diagnostics, and vaccines. However; one of the main obstacles to the 
study of antigen specificity in human T cells is their low frequency in PBMC samples. To overcome this problem we 
have implemented strategies to generate memory T cell libraries and clones specific to the pathogen of interest. Due 
to the fact that memory T cells represent a repository of the human T cell response to infection, examination of their 
antigen specificity can efficiently reveal immunogenic and relevant antigens involved in the in vivo response to 
infection or vaccines. To examine the specificity of the memory T cells we use an unbiased collection of antigens 
together with an in silico analysis, namely positional scanning based biometrical analysis. Here we present a summary 
of our approach and ongoing work on the development of strategies for the culture of memory T cells from patients 
with Chagas disease. While most studies focus on the identification of vaccine candidates using preselected 
immunogenic proteins derived from animal models or by or bioinformatics prediction, here we present an innovative 
approach that directly examines the specificity of the memory response following infection or immunization in 
humans. 
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1. Introduction 
To date, several studies aimed to identify T cell vaccine candidates have used preselected immunogenic proteins 
derived from experimental analysis on animal models or by bioinformatics prediction of MHC binding. While it is 
feasible to obtain candidate genes or proteins from bioinformatics analysis, their validation as immunogens is critical 
and more difficult, requiring further characterization of their immune recognition in humans. Here we describe the 
advantages and future required optimization steps to a “T cell driven” approach developed by our laboratory that uses 
human peripheral blood mononuclear cells (PBMC) from vaccinated or infected human patients to generate pathogen 
specific memory T cell libraries and clones to directly examine their specificity using an unbiased collection of 
peptides named positional scanning peptide libraries.  
2. Results 
The approach presented here consists of 3 steps: 1) the generation of T cell libraries representing the human memory 
response to infection or vaccination, 2) the generation of pathogen specific T cell clones and, 3) the screening of the 
pathogen specific T cell clones with positional scanning peptide libraries to identify pathogen immunogenic proteins 
(Figure 1).   
 
The 3 steps of the approach have been validated by our work and the work of others. Specifically, the generation 
of T cell libraries has been successfully used by Lanzavecchia’s group to study the immune response to naturally 
processed parasite antigens from tetanus toxoid, cytomegalovirus and purified protein derivative1 and more complex 
pathogens such as S. pyogenes, S. aureus and C. albicans2,3. In addition, work from our laboratory in collaboration 
with the Chagas Laboratory at Instituto de Investigaciones en Ingeniería Genética y Biología Molecular in Buenos 
Aires, Argentina, has focused on the optimization of several experimental parameters in order to successfully recover 
the memory response to T. cruzi infection in several patients at different stages of the disease (manuscript in 
preparation). In regards to steps 2 and 3, they have been extensively implemented in our laboratory. We have 
demonstrated the elucidation of T cell specificity using positional scanning peptide libraries in combination with in 
silico analysis with protein databases (biometrical analysis). A number of studies with clones of known specificity  has 
been used to develop the methodology and revealed that the known antigens for most clones rank among the top 50 
predicted stimulatory peptides, reviewed in4. Furthermore, as shown in table 1, the methodology was successfully 
utilized for clones of unknown specificity. 
 
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license 
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Table 1. Use of approach with T cell clones of unknown specificity. 
 
Disease/T cell clone Generated with Protein Databases used for  
Biometrical analysis 
Reference 
Lyme/CD4 Borrelia lysate Borrelia and human 5 
Melanoma/CD8 PHA Human 6 
Multiple Sclerosis/CD4 
Diabetes/CD4 
PHA 
- 
Human and virus  
Bacteria and virus 
7,8 
9 
Smallpox-Vaccinated donors Vaccinia virus Western Reserve vaccinia virus 10,11 
Chronic beryllium Disease Beryllium Human 12 
 
One of the great advantages of this approach is that the identified parasite proteins are by definition immunogenic 
in humans as they are recognized by T cells expanded in vivo during infection or vaccination. In the particular case of 
infections for which vaccines are needed, the identified antigens constitute a database of confirmed immunogenic 
proteins and therefore can be considered as biomarkers or vaccine candidates. The approach is solely based on the 
integration of the screening results of an unbiased source of peptides, namely a positional scanning library, with the 
protein database of the pathogen of interest. The screening of the T cell libraries has been successfully carried out 
using autologous PBMCs or B-cell lines13. The approach neither uses MHC binding prediction algorithms based on 
HLA haplotype nor requires the a priori knowledge of the MHC restriction of the T cell clones to be studied.  
Furthermore, the information related to the HLA of the target population or the HLA associated to the immune 
response to the pathogen of interest are not always available.  Additionally, being unbiased with respect to the HLA 
is also advantageous since it is clearly possible that a novel immunoprevalent identified protein binds to an HLA type 
that was previously not known to be associated to the immune response to the pathogen. Thus, it is possible that by 
utilizing the presented approach novel proteins and HLA binding associations can be established. Furthermore, in 
regards to T cell driven vs. MHC driven approaches we have recently published a statistical analysis comparing the 
efficiency of both methodologies on the identification of immunoprevalent vaccinia antigens. The analysis showed 
that in general T cell driven approaches are more effective than MHC approaches in identifying predominantly 
recognized proteins11. 
 
Another key feature of the presented approach is that depending on what question is to be addressed, the source of 
human/PBMC samples for the generation of T cell libraries and clones, can be adapted to answer accordingly. For 
example, in the case of our work with vaccinia virus, the goal of the study was to understand which key proteins were 
involved in the immune response to vaccinia upon smallpox vaccination with the Dryvax vaccine in humans. This was 
particularly important in the context of determining if other vaccine candidates such as Modified Vaccinia Ankara 
would elicit comparable responses to Dryvax14. Therefore, in order to help answering this question, T cell clones 
specific to vaccinia were derived from Dryvax immunized subjects and screened with positional scanning peptide 
libraries to reveal their specificity10.  
 
A more complex example is represented with our current collaborative work on Chagas disease. The protozoan 
parasite T. cruzi is the causative agent of Chagas, and is a prominent human health problem in Central and South 
America.  The incidence of T. cruzi infection has been reduced by international efforts to control the vector and to 
improve the safety of blood transfusions. However, it is estimated that up to 10 million people worldwide have chronic 
infection that may lead to the development of severe Chagas disease, and of those 50,000 will die each year due to 
different complications caused by the infection. The acute phase of T. cruzi infection is short-lived and in some cases 
accompanied by mild illness. However, on the great majority of the individuals the parasite will persist for 10-30 years 
as an asymptomatic infection (chronic asymptomatic patients) before it manifests as serious cardiac and/or digestive 
complications in 20-40% of cases (clinical patients)15. Despite its enormous impact on public health, control of T. cruzi 
infection is hampered by the absence of a protective vaccine. Thus, the objective of our work is to identify 
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immunogenic T. cruzi antigens. To do this, our approach directly focuses on generating T cell libraries and clones 
from chronic asymptomatic patients. The advantage of focusing on this population relies on the fact that most likely 
these patients have been able to control the infection and therefore, likely to recognize parasite antigens involved in 
protection. It is also important to remark that in the Chagas field, shortlisting the antigens capable of inducing 
immunity against T. cruzi infection has been very difficult in part due to the fact that T. cruzi encodes approximately 
10,000 proteins. In this regards, another advantage of the present methodology is that it does not require a priori 
selection of parasite antigens and thus it can be used to identify immunogenic proteins from large pathogens for which 
another methodologies would be more limiting. 
 
There are some steps on the methodology that could be optimized in order to improve throughput. For example, the 
cloning of pathogen specific T cells by limiting dilution remains a very time consuming task and therefore decreases 
the throughput of the approach. In this regards, a recent work by Neller et al.16  showed the generation of human 
effector T cell clones by combining an optimized IFN-γ capture assay with the sorting of single effector T cells directly 
into multi-well plates using a flow cytometer equipped with a single cell deposition unit. This rapid and highly efficient 
method for cloning effector CD4+ and CD8+ T cells ex vivo enables the selection of specific T cell clones without the 
need for multiple initial rounds of in vitro stimulation and cell division. We plan to evaluate the cloning strategy 
recently presented by Neller et al. for the cloning step included in our approach. This could improve the efficiency on 
the cloning step and thus on the number of pathogen antigens identified per subject. 
 
Another limiting step of our approach is that clonal cells need to be grown to large numbers (15-30 millions) in 
order to be screened with the positional scanning peptide libraries. We believe that further efforts on the development 
of miniature T cell activation assays will be extremely beneficial to reduce the number of clonal T cells required to 
test combinatorial peptide libraries and to be able to define the spectrum of specificities with higher throughput. Steps 
towards achieving this goal have already been initiated. For example, we have demonstrated that significant lower 
antigen concentrations are required for substantial production of GM-CSF by T cells as compared to other cytokines. 
This makes the detection of GM-CSF a very sensitive readout and may allow decreasing the number of cells needed 
for the screening. Although this has already been demonstrated for vaccinia virus10, experiments using T. cruzi specific 
T cells also showed similar results17. 
 
3. Conclusions 
Recognized and neglected infectious diseases call for innovative and efficient approaches to identify the candidate 
pathogen antigens that can be considered for vaccine design and development. In this regards, it is important to 
highlight that in infectious diseases, such as Chagas disease, in which the causing pathogen encodes for a large number 
of proteins and the infection causes a chronic asymptomatic state of the disease in a proportion of the patients, the 
presented approach is expected to be a good tool capable of combining correlates of protection with a methodology 
that does not need any a priori knowledge of candidate immunogenic proteins. By focusing on memory T cell libraries 
from samples derived from patient populations that have been able to control the infection for a large period of time, 
it can be hypothesized that the immunoprevalent proteins derived from this study could be involved in the protective 
immune response to the pathogen and thus will constitute a defined database of vaccine candidates to accelerate the 
design of a novel preventive and/or therapeutic Chagas vaccine. 
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